March 05, 2018
Safety Analysis of Leishmania Vaccine Used in a Randomized Canine Vaccine/Immunotherapy Trial
In Leishmania infantum–endemic countries, controlling infection within dogs, the domestic reservoir, is critical to public health. There is a need for safe vaccines that prevent canine progression with disease and transmission to others. Protective vaccination against Leishmania requires mounting a strong, inflammatory, Type 1 response. Three commercially available canine vaccines on the global veterinary market use saponin or inflammatory antigen components (Letifend) as a strong pro-inflammatory adjuvant. There is very little information detailing safety of saponin as an adjuvant in field trials. Safety analyses for the use of vaccine as an immunotherapeutic in asymptomatically infected animals are completely lacking. Leishmania infantum, the causative agent of canine leishmaniasis, is enzootic within U.S. hunting hounds. We assessed the safety of LeishTec® after use in dogs from two different clinical states: 1) without clinical signs and tested negative on polymerase chain reaction and serology or 2) without clinical signs and positive for at least one Leishmania diagnostic test. Vaccine safety was assessed after all three vaccinations to quantify the number and severity of adverse events. Vaccinated animals had an adverse event rate of 3.09%, whereas placebo animals had 0.68%. Receiving vaccine was correlated with the occurrence of mild, site-specific, reactions. Occurrence of severe adverse events was not associated with having received vaccine. Infected, asymptomatic animals did not have a higher rate of adverse events. Use of vaccination is, therefore, likely to be safe in infected, asymptomatic animals.
Read the full article in The American of Tropical Medicine and Hygiene.
More from CNAS
-
CNAS Insights | Can the United States Sustain Its War Against Iran?
Commentary
As Operation Epic Fury nears its one-week mark, the Trump administration is preparing to host U.S. defense companies at the White House for a discussion on defense production....
By Stacie Pettyjohn & Philip Sheers
-
Deterrence at Scale
Commentary
Introduction From the Punic Wars to Franco-Prussian competition in the Renaissance to World War II, history is replete with examples of when industrial capacity—not simply tac...
By Jennifer McArdle
-
Commentary
Defense / Middle East Security
Iran, Israel, and the U.S. Are Racing the ClockThis article was originally published in Foreign Policy. At first glance, the Israeli-U.S. attack on Iran is an uneven fight. The United States and Israel have overwhelming ai...
By Franz-Stefan Gady
-
Eyes in the Sky
Reports
Executive Summary In the Department of Defense’s priority scenarios—a “defense by denial” of China and homeland defense—dedicated airborne sensing and battle management aircra...
By Philip Sheers
